Literature DB >> 20651078

Proteasome and HDAC: who's zooming who?

David McConkey1.   

Abstract

Year:  2010        PMID： 20651078     DOI： 10.1182/blood-2010-04-278507

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

Review 2.  Bortezomib combination therapy in multiple myeloma.

Authors:  Prashant Kapoor; Vijay Ramakrishnan; S Vincent Rajkumar
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Authors:  Michael Millward; Timothy Price; Amanda Townsend; Christopher Sweeney; Andrew Spencer; Shawgi Sukumaran; Angie Longenecker; Lonnie Lee; Ana Lay; Girish Sharma; Robert M Gemmill; Harry A Drabkin; G Kenneth Lloyd; Saskia T C Neuteboom; David J McConkey; Michael A Palladino; Matthew A Spear
Journal:  Invest New Drugs       Date:  2011-11-12       Impact factor: 3.850

4.  Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.

Authors:  Maria Saveria Gilardini Montani; Marisa Granato; Claudio Santoni; Paola Del Porto; Nicolò Merendino; Gabriella D'Orazi; Alberto Faggioni; Mara Cirone
Journal:  Cell Oncol (Dordr)       Date:  2017-02-03       Impact factor: 6.730

5.  Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.

Authors:  Charvi Nanavati; Donald E Mager
Journal:  AAPS J       Date:  2021-08-17       Impact factor: 4.009

6.  The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.

Authors:  Jiro Kikuchi; Satoshi Yamada; Daisuke Koyama; Taeko Wada; Masaharu Nobuyoshi; Tohru Izumi; Miyuki Akutsu; Yasuhiko Kano; Yusuke Furukawa
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

Review 7.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

Review 8.  The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.

Authors:  Maria Cosenza; Samantha Pozzi
Journal:  Int J Mol Sci       Date:  2018-08-09       Impact factor: 5.923

9.  HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Authors:  Hongbiao Huang; Ningning Liu; Changshan Yang; Siyan Liao; Haiping Guo; Kai Zhao; Xiaofen Li; Shouting Liu; Lixia Guan; Chunjiao Liu; Li Xu; Change Zhang; Wenbin Song; Bing Li; Ping Tang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.

Authors:  Maolin Ge; Dan Li; Zhi Qiao; Yan Sun; Ting Kang; Shouhai Zhu; Shifen Wang; Hua Xiao; Chunjun Zhao; Shuhong Shen; Zhenshu Xu; Han Liu
Journal:  Oncogene       Date:  2020-07-30       Impact factor: 9.867
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.